HR Execs on the Move

Albireo Pharma

www.albireopharma.com

 
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo`s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo`s clinical pipeline also includes two Phase 2 product candidates. Albireo`s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Brian DiMarco
Senior Director, Marketing Profile
Kosta Haveles
Senior Director, Talent Acquisition Profile

Similar Companies

Oxis International

Oxis International, Inc. has formed and provided initial financing to support the activities of its wholly owned subsidiary, Oxis Biotech, Inc. The parent company, Oxis International is engaged in the research, development and sale of products to counteract oxidative stress and inflammation. Oxis Biotech is focused on the acquisition of cannabis related intellectual properties and commercialization of therapies developed from the intellectual properties to treat certain diseases.

RTI Surgical®

RTI Surgical (RTI) is a global, industry leading surgical implant supplier that provides design, new product development, processing and manufacturing services in support of patients and leading medical technology companies. With expertise spanning tis...

Ridgmar Pharmacy

Ridgmar Pharmacy is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

NS Pharma

NS Pharma is a biopharmaceutical company focused on researching and developing treatments for rare diseases, with a current focus on optimizing exon skipping therapy for Duchenne muscular dystrophy.